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The utility of matrix-assisted laser desorption mass spectrometry for characterizing products 
of in vitro processing of synthetic dynorphin A (Dyn A) peptides in biologic matrices is 
described. A series of laser desorption matrices were tested for their response to Dyn A (l-6), 
Dyn A (l-7), Dyn A (l-8), Dyn A (l-9), Dyn A (l-lo), Dyn A (l-13), Dyn A (Z-17), and Dyn A 
(1-17). a-Cyano+hydroxycinnamic acid was chosen as a suitable matrix for subsequent 
studies. Mass spectra of dynorphin peptides indicated a good signal-to-noise response down 
to (1) 10 fmole of Dyn A (l-10) amide standard in aqueous acidic solution and (2) a 
concentration of 1O-7 M for seven dynorphin peptides spiked into human plasma. Two 
examples of the mass spectrometric analysis of the products of in vitro processing are 
presented: Dyn A (l-13) and Dyn A (l-17) in human blood. The presence and identity of 
processed peptides can be simply inferred from the molecular masses provided by the mass 
spectrometric measurement without extensive sample purification. A comparison of matrix- 
assisted laser desorption mass spectrometry is made with high-performance liquid chro- 
matography. (J Am Sot Mass Specfrom 1994, 5, K-16) 
A 
number of studies using mass spectrometric 
techniques have been reported for characteriz- 
ing and measuring neuropeptide levels in hu- 
man and animal tissues and fluids [l-5]. For example, 
fast-atom bombardment mass spectrometry, coupled 
with extensive multidimensional reversed-phase high- 
performance liquid chromatography (HPLC), has been 
used in the analysis of endogenous met-enkephalin [ 11, 
Pendorphm [2], dynorphin (Dyn) A (l-6), and Dyn B 
(7-13) [3] in human pituitary and met-enkephalin in 
human cerebrospinal fluid [4]. Recently, electrospray 
mass spectrometry was used to determine endogenous 
met-enkephalin and Pendorphln levels extracted from 
human pituitary gland [5]. 
Matrix-assisted laser desorption mass spectrometry 
[6-81 is also a powerful analytical method for analyz- 
ing peptides and proteins. Among the strengths of the 
technique are its high sensitivity [9, 101; its ability to 
examine, simultaneously and without extensive chro- 
matographic purification, many peptide and protein 
components in a complex mixture [ll]; and its facility 
for making such measurements on mixtures containing 
large quantities of nonprotemaceous impurities (e.g., 
salts) [ll]. 
We report here the development of a matrix- 
assisted laser desorption mass spectrometry technique 
to characterize processing in body tissues and fluids of 
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exogenously added or administered neuropeptides. In 
this study, two examples of the mass spectrometric 
analysis of the products of in vitro processing are 
presented: Dyn A (l-13) [12] and Dyn A (1-17) in 
human blood. The presence and identity of processed 
peptides can be readily inferred from the mass spectro- 
metric measurement. A comparison of the present 
technique is made with standard HPLC analysis. 
Materials and Methods 
Dynorphin Peptides 
The dynorphin peptide standards Dyn A (l-6), Dyn A 
(l-7), Dyn A (l-8), Dyn A (l-9), Dyn A (l-lo), Dyn A 
(l-10) amide, Dyn A (l-13), Dyn A (Z-17), and Dyn A 
(l-17) were purchased from Peninsula Laboratories 
(Belmont, CA). Some of these peptide standards [Dyn 
A (l-9), Dyn A (l-13), and Dyn A (l-17)] were also 
obtained from Multiple Peptide Systems (San Diego, 
CA) and made available by the National Institute on 
Drug Abuse (NIDA). Dyn A (l-13), used in the human 
blood processing study, was generously donated by 
Neurobiological Technologies Inc. (Richmond, CA). 
This sample of Dyn A (l-13) contained mannitol as an 
excipient prepared for human use. The ammo acid 
sequence of Dyn A (l-17) is given in Figure 1. HPLC- 
grade acetonitrile was purchased from Burdick& 
Jackson (Muskegon, MI) and trifluoroacetic acid (TFA) 
from Fisher Scientific (Fair Lawn, NJ). 
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Dyn A (1-17) 
P/R-GLY-GLY-PHE-LEU-ARO-ARQ-ILE-ARG-PRO-SN.GLN 
1 2 3 a I 6 7 8 9 10 11 12 13 14 15 16 17 
. Dyn A (l-13) 
Figure 1. The amino acid sequence of dymrphin A (l-17). 
Matrix-assisted Laser Desorption 
Mass Specfromety 
The matrix-assisted laser desorption mass spectcomet- 
ric measurements were carried out with a linear ticne- 
of-flight mass spectrometer and laser desorption ion 
so&e constructed at the Rockefeller University. De- 
tails of the instcument and the data acquisition/analy- 
sis methods have been described previously [9,11-131. 
The peptide samples were prepared for mass spectco 
metric analysis by mixing them with concentrated so- 
lutions of a variety of different matrix compounds: 
sinapinic acid, feculic acid, caffeic acid, n-cyano-4- 
hydcoxycinnamic acid, and a-cyano-3-hydroxycin- 
namic acid (Aldrich, Milwaukee, WI); 2,5-dihydroxy- 
becuoic acid (Sigma Chemical Co., St. Louis, MO); and 
3-indoleacrylic acid (Fluka AG, Buchs, Switzerland). 
The matrix compounds were dissolved at a saturation 
concentration of 5 to 10 g/L in 33% acetonitcile and 
67% of 0.1% aqueous TFA (v/v). Adjustments of the 
organic/aqueous ratio were sometimes needed to 
maximize the matcix concentration. The samples and 
standards were also dissolved in solutions of similar 
organic/aqueous ratio, Typically, 2 FL of matrix solu- 
tion and 2 PL of peptide sample solution were mixed, 
and about 0.5 PL of the mixture was applied to the 
mass spectrometer sample probe tip, which is 2 mm in 
diameter. The liquid was dried with a stream of cool 
forced air. The probe tip was inserted into the mass 
spectrometer through a sample look, and the spectrum 
acquired after a few minutes of vacuum pumping to 
allow the pressure to reach approximately 10m7 torr 
and to thoroughly remove residual solvents from the 
sample. The UV laser wavelength was set at 355 nm. 
The laser pulse duration was approximately 10 ns, and 
the power density deposited on the sample probe was 
approximately lo6 watts/cm’. The individual spectra 
from 100 laser shots were averaged to obtain a mass 
spectrum exhibiting good statistics. With the laser op- 
erating at a repetition rate of 2.5 pulses/s, the acquisi- 
tion of a spectrum was completed in 40 s. 
Separation Methods Used Prior to Matrix-assisted 
Laser Desorption Mass Spectromefy 
The separation methods used to remove potentially 
interfering contaminants in human plasma included 
Sep-pak mini-extraction cartridges and membrane fil- 
tees with 3000 or 5000 Da molecular weight (Mw) 
cut-off. The solid phase Cc, Sep-pak extraction columns 
(Waters-Millipoce, Milfocd, MA) were activated by a 
wash with acetonitcile followed by 0.1% TPA in H,O. 
Typically, 1 mL of plasma sample was diluted in 5 to 
10 mL of 0.1% TFA, and the resulting mixture was 
applied to the activated Cc, minicohunn. A vacuum 
was applied to initiate and sustain the flow. The 
columns were washed with 0.1% TFA in H,O three 
times and partially dried for a minute by drawing air 
through with the application of vacuum. The peptides 
were eluted by acetonitcile @O-80%) in 0.1% TFA. The 
eluate was placed in a speed vacuum concentrator 
(Savant hshwnenk, Farmingdale, NY) and the vol- 
ume reduced until a 10 to 20 PL residue of the eluate 
remained. The cesulting peptide solution was com- 
bined with the matrix solution for mass spectcometcic 
analysis. 
The membrane filters were made of regenerated 
cellulose with 3000 Da Mw cut-off (Centcicon 3 micro- 
concentrators, Amicon-Gcace, Beverly, MA) or 5000 Da 
Mw cut-off (UltrafreeCl filters, Millipoce, Milfocd, 
MA). The low molecular weight peptides of interest 
were separated from the high molecular weight pro- 
teins in plasma by centcifugation (3000-4000 g) at low 
temperature (4 “C). Prior to use, the filters were washed 
sequentially with 2 mL each of deionized H,O, 0.1 M 
NaOH, warm H,O (- 70 “C), and 0.1% TPA to ce- 
move contaminating chemicals that often reduce the 
laser desocption mass spectcometcic response. Typi- 
cally, 0.3 mL of plasma sample was diluted with 1.7 
mL of 0.1 to 0.5% TFA in H,O. The diluted mixture 
was pipetted into a microconcentrator containing a 
membrane filter and centrifuged (4 “C) for 2 h. The 
filtrate was placed in a speed vacuum concentcatoc 
until its volume was reduced to 10 to 20 PL for 
subsequent mass spectrometcic analysis. 
HPLC Methods Used for Comparison with 
Matrix-assisted Laser Desorption 
Mass Specfromety 
Chromatogcaphic analysis was performed using a 
SMART microbore HPLC system (Phacmacia LKB 
Biotechnology, Piscataway, NJ) fitted with a C2/C,, 
reverse phase column (3.2 mm X 3.0 cm) with a UV 
detector (254 nm). The mobile phase was made up of 
two components: component A consisting of 0.1% TPA 
in Hz0 and component B consisting of 80% acetoni- 
tcile in 20% of 0.1% TPA. The flow rate was 300 
@L/nun. The separation method used for this compar- 
ison consisted of an initial aqueous mobile phase (0% 
B for 6 min and O-10% B in 5 min), followed by a 
gradient with a low rate of change (lo-20% B in 24 
min). After the gradient separation, the column was 
washed with 100% B for 10 mm. The standard mixture 
of eight dynorphin peptides (10 ILL, 10m5 M) was 
injected into the SMART system, and fractions contain- 
ing all the chcomatogcaphic peaks were collected for 
subsequent mass spectrometcic analysis. 
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Results and Discussion 
Matrix Selecfiun for Dynorphin Peptide Analysis 
To obtain an optimal matrix-assisted laser desorption 
mass spectrum for a given application, it is necessary 
to select an appropriate matrix [6, 7, 10, 141. A mixture 
of dynorphm standards-Dyn A (l-61, Dyn A (l-7), 
Dyn A (l-81, Dyn A (l-9), Dyn A (l-101, Dyn A (l-131, 
Dyn A (2-17), and Dyn A (l-17)--was used to deter- 
mine the response of the mass spectrometer to a selec- 
tion of commonly used matrices (Figure 2). The amount 
of each peptide in the matrix solution applied to the 
probe of the mass spectrometer was 0.4 to 0.5 pmole. 
The spectra obtained from a-cyano-4-hydroxycinnamic 
(Figure 2a) and 3-indoleacrylic acids (Figure 2b) indi- 
cated that both are effective matrices for the dynorphin 
peptides. However, a-cyano4-hydroxycinnamic acid 
offered a slightly stronger and more stable response 
than 3-indoleacrylic acid with a lower background 
below m/z 1000. Caffeic acid was also an effective 
matrix for these peptides (Figure 2~). However, it 
proved difficult to produce spectra uniformly from all 
positions on the probe tip because only selected areas 
yielded intense spectra. A significant amount of effort 
was required to obtain the spectrum shown in Figure 
2c. Ferulic acid was a less effective matrix for these 
peptides, producing a relatively weaker response (Fig- 
ure 2d). Although sinapinic acid generated quite strong 
spectra (Figure 2e) for peptides of larger masses, Dyn 
A (Z-17) and Dyn A (l-171, the signal quality was 
reduced for the lower mass peptides. aCyano3- 
hydroxycinnamic acid and 2,5-dihydroxybenzoic acid 
produced fairly good spectra of all the peptides, but 
again it proved necessary to search the probe tip for an 
area that yielded an intense spectrum. 
These responses for the dynorphin peptides in the 
different matrices tested are in general agreement with 
previous findings by this and other groups [lo-181. 
u-Cyano4-hydroxycinnamic acid has recently been 
demonstrated to be an excellent matrix for a variety of 
biopolymers [IS]. However, one practical complication 
was the frequent formation of intense adduct species 
of copper with the peptides, occurring as a result of 
the presence of trace amounts of adventitious copper 
impurities of unknown origin [18]. In the present ap- 
plication, copper adduction is not a serious problem 
because the resulting adduct peaks in the spectrum are 
well resolved for the peptides of interest. Thus, (Y- 
cyano-4-hydroxycinnamic acid was chosen as the ma- 
trix for all subsequent analyses. We have found that 
this matrix also tolerates a large molar excess of ir- 
volatile inorganic contaminants (e.g., salts) over the 
peptides of interest. For example, a mixture of the 
eight dynorphin standards in a-cyano-4-hydroxycin- 
namic acid, in which a 100,000 molar excess of phos- 
phate buffer was present, produced a mass spectrum 
indistinguishable from the spectrum taken without 
added buffer (Figure 2a). 
500 
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Figure 2. Matrix-assisted laser desorption mass spectrum of 
eight dynorphin standards in various matrices. (a) u-Cyano-4- 
hydroxycinnamic acid, (b) 3.indoleacrylic acid, (c) caffeic acid, 
(d) ferulic acid, and (e) sinapinic acid. The peak corresponding to 
Dyn A (l-6) is labeled 1-6. The other peaks are labeled using the 
same nomenclature. 
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Sensitivity for Detecting Dynorphin Peptides 
Dilution studies using dynorphin standards showed 
that laser desorption mass spectrometry is a very sen- 
sitive method for detecting these peptides. A constant 
amount of angiotensin III (80 fmole) &as used as an 
internal standard. The peak intensity ratio of Dyn A 
(l-10) amide to angiotensin III was plotted as a func- 
tion of the amount of Dyn A (l-10) amide on the probe 
tip, as shown in Figure 3. At the lowest level investi- 
gated, a total amount of 10 fmole of Dyn A (l-10) 
amide applied to the 2-mm diameter probe tip yielded 
a protonated molecular ion peak having a signal-to- 
noise ratio of 27:l. 
Effect of the Biologic Matrix on the tiss 
Spectrometric Detection of Dynorphins 
The results obtained from the dynorphin standards 
encouraged us to examine the matrix-assisted laser 
desorption mass spectrometric response to dynorphin 
peptides spiked into plasma. The human plasma (New 
York Blood Center) used in these experiments was 
treated by chemical agents, which would be expected 
to deactivate most plasma enzymes. The plasma sam- 
ples spiked with dynorphin standards were subjected 
to various extraction schemes to establish a method for 
retaining the maximum amount of the dynorphins of 
interest while removing as many of the interfering 
proteins, peptides, and other contaminating com- 
pounds as possible. Two techniques emerged as the 
most satisfactory. Plasma samples with the added 
dynorphin peptides were diluted with a fivefold to 
tenfold excess volume of acidic aqueous solution 
(O.l-0.5% TFA in deionized water). In the first tech- 
nique, the diluted mixture was subjected to C,, Sep- 
pak column extraction, whereas in the second tech- 
Figure 3. The intensity ratio of the Dyn A (l-10) amide peak to 
the angiotensin III peak as a function the amount of Dyn A (l-10) 
amide on the probe tip. The amount of angiotensin III was kept 
constant at 80 fmole. The reproduc12iIity of the ratio deterrnina- 
tion is indicated by tlvee replicate measurements obtained from 
1 pmole of Dyn A (l-10) amide. 
nique, separation was achieved by filtration through 
membranes with 3000 or 5000 Da Mw cut-off. Filtra- 
tion using the membrane filters was found to be a 
straightforward and efficient first step for removing 
plasma proteins. Although the C,, Sep-pak column 
was similarly effective in removing plasma proteins 
and salts, the recovery of peptides from the Sep-pak 
columns was reduced rapidly as the dynorphin con- 
centration was lowered toward 10? M. 
A spectrum of a mixture of seven dynorphins spiked 
into plasma is shown in Figure 4. The initial concentra- 
tion of each dynorphin in the human plasma was 10m7 
M in a total plasma volume of 200 pL. This sample 
was prepared by diluting 1 PL of a standard solution 
of seven peptides (20 FM) into 200 PL of plasma. The 
spiked plasma was diluted with 2 mL of 0.1% TFA, 
and the resulting solution was filtered through a 3000 
Da Mw cut-off membrane filter. The filtrate was placed 
in a speed vacuum concentrator until its volume was 
reduced to about 10 PL for mass spectrometric analy- 
sis. Only one-fortieth of this total sample (0.5 pmole of 
each peptide) was filly subjected to mass spectrcF 
metric analysis. All of the spiked dynorphin peptides 
are readily identified in Figure 4, although the signal 
intensities are weaker than those of the standards in 
acetonitrile/O.l% TFA (Figure Za). This reduction in 
response likely arises from losses that occurred during 
the filtration and from interference of residual contam- 
inants. A large quantity of salt passes through the 
membrane filter. Therefore, a rapid wash (1 s) of the 
probe tip was needed to remove these salts using cold 
(4 “C) aqueous acidic solution (in which the matrix is 
relatively insoluble). The same sample preparation 
method was used in the subsequent analysis of dynor- 
phin processing in human blood, 
Figure 4. Matrix-assisted laser desorption mass spechum of 
sewn dynorphin standards spiked into human plasma at a con- 
centration of lo-’ M for each peptide (see text). Sodium adducts 
are indicated as y, copper adducts are indicated as x, and the 
unidentified peaks are marked as u. 
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In Vitro Processing of Dyn A (l-23) and Dyn A 
(l-17) in Human Blood 
In preparation for proposed dynorphin peptide phar- 
macokinetic studies in humans, it is essential to ascer- 
tain (1) whether dynorphin maintains its integrity after 
intravenous administration and (2) whether any fur- 
ther processing of dynorphin peptides occurs in fresh 
blood (without or with addition of enzyme inhibitors) 
after it is drawn from a person. As an initial step to 
address both of these questions, studies were per- 
formed to determine the in vitro processing of Dyn A 
(l-13) and Dyn A (l-17) in freshly drawn human blood. 
A relatively high concentration (10m4 M, 150 PL) of 
Dyn A (l-13) was immediately added (delay time < 30 
s) into freshly drawn blood (1.5 mL) taken from nor- 
mal healthy human volunteers after the blood was 
collected in a sterilized lo-mL VACUTAINER tube 
(Becton Dickinson, Rutherford, NJ). To obtain plasma, 
the spiked blood was promptly centrifuged at 4 “C for 
5 min at 2500 g. In the same manner as described in 
part c for the sample shown in Figure 4, the plasma 
samples were diluted with 0.1% TFA, filtered through 
3000 Da Mw cut-off membrane filter, and the filtrate 
concentrated before mass spectrometric analysis. 
Figure 5a shows the mass spectrum of the peptides 
extracted from plasma separated from spiked blood 
immediately after Dyn A (l-13) was added (0 min 
waiting time). The processed products were identified, 
from the molecular weights of the peaks, as Dyn A 
(l-6), Dyn A (2-11) or (4-12), Dyn A (3-121, Dyn A 
(2-121, and Dyn A (l-12). The masses were determined 
with an accuracy of better than + 0.4 Da, so that all but 
one of the peptides could be identified unambigu- 
ously. The calculated molecular weight difference be- 
tween Dyn A (2-11) and Dyn A (4-12) is only 0.9 u. 
Because the observed mass of one product fell behveen 
the two calculated molecular weights, there is uncer- 
tainty as to the identity of this product. The observed 
rapid cleavage of the amino terminal tyrosine and the 
carboxyl terminal lysine of Dyn A (l-13) has been 
reported previously in studies of processing of Dyn A 
(l-13) in rat brain in vitro [19,20]. 
The results of a similar study of in vitro processing 
of Dyn A (l-17) in human blood is shown in Figure 5b. 
Dyn A (l-17) (10m4 M, 150 PL) was immediately 
added to freshly drawn human blood (1.5 mL) to yield 
a final concentration of 10 m5 M, whereupon the plasma 
was separated promptly (0 min waiting time). In Fig- 
ure 5b, the compound giving rise to the predominant 
peak is unprocessed Dyn A (l-17), whereas the major 
products of processing are identified as Dyn A (9-171, 
Dyn A (8-171, Dyn A (7-171, Dyn A (l-6), and Dyn A 
(2-17). The mass spectrum of a control sample of hu- 
man blood with no added dynorphin A peptides is 
given in Figure 5c. No peaks were observed in this 
control spectrum that corresponded to any processed 
products from Dyn A. Further study is being con- 
ducted to examine the details of the differential pro- 
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500 
Figure 5. Matrix-assisted laser desorption rna~ spectra of 
dynorphin peptides after in vitro processing in human blood. The 
starting peptides and the time periods that the spiked blood was 
kept on ice were (a) !+I A (l-13), 0 min; and (b) Dyn A (l-17),0 
min. The small peaks on the high mass side of the major peaks 
arise from sodium, potassium, and copper adduct species, re- 
spectively [28]. The unidentified peaks are marked as u. (cl The 
mass spectrum obtained from a sample of human blood with no 
added Dyn A peptide. 
cessing of Dyn A (l-13) and Dyn A (l-17) in human 
blood and to study the appearance and disappearance 
of metabolites as a function of time (Chou et al., 
manuscript in preparation). 
Contrasting Matrix-assisted Laser Desorption Mass 
Spectromety with HPLC Analysis of Dynorphin 
Peptide Mixtures 
HPLC is a widely used technique for the separation 
and quantitation of neuropeptides 1211. However, 
HPLC alone cannot always determine the identity of a 
single peptide or a mixture of peptides in a given 
chromatographic peak, even when all of the peptides 
possibly present are available to be used as standards. 
J Am Sot Mass Spectrom 1994,5,10-16 
Laser desorption mass spectrometry proves useful for 
identifying the molecular weights of putative individ- 
ual components separated by HPLC, and thus removes 
some of the ambiguity inherent in HPLC. For example, 
Figure 6a shows an HPLC chromatogram of 10 kL of a 
dynorphin standard mixture (10m5 M in 0.1% aqueous 
TFA) that contained Dyn A (l-6), Dyn A (l-7), Dyn A 
Cl-S), Dyn A (l-91, Dyn A (l-lo), Dyn A (l-13), Dyn A 
(2-17), and Dyn A (l-17). The mixture was injected into 
the SMART system with a programmed method de- 
scribed in the Method section. Each chromatographic 
peak was fraction-collected from the microbore HPLC 
and concentrated for mass spectrometric analysis. Al- 
though six of the seven chromatographic peaks corre- 
sponded to individual dynorphin peptides (Figure 6a), 
the mass spectrum of the fraction corresponding to the 
seventh peak (peak A) clearly revealed the presence of 
two dynorphin peptides: Dyn A (l-8) and Dyn A (l-10) 
(Figure 6b). The two peptides coeluted, yielding a 
Qyn A (l-8) 
b 
Dyn A(l-10) 
Figure 6. (a) A microbore high-performance liquid chro- 
matogram of a mixture of dynorphin standards. The fractions 
of chmmatographic peaks are collected and identified by laser 
desorption mass spectmmetry. The indicated fraction A was 
collected for mass spectrornetric analysis. (b) The mass spechum 
of fraction A. Two peptides were found in the single chromato- 
graphic peak. 
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single chromatographic peak even in a gradient with a 
low rate of change (see Experimental section). In the 
absence of mass spectrometry, the identification of 
these two coeluting dynorphin peptides would be 
problematic. 
In addition, matrix-assisted laser desorption mass 
spectrometry was found to be highly effective despite 
the presence of a large amount of residual impurities 
in the samples (e.g., peptides, salts, and lipids). Be- 
cause of this high tolerance for impurities, the sample 
purification/preparation steps required prior to mass 
spectrometric analysis are not more stringent than those 
required prior to HPLC. The sensitivity and speed of 
the laser desorption mass spectrometric analysis are 
comparable to or faster than standard microbore HPLC 
analysis. 
HPLC has been developed for quantitation of some 
peptides under optimized conditions. By contrast, 
quantitative analysis using matrix-assisted laser de- 
sorption mass spectrometry has yet to be developed 
(work in progress). However, initial studies of the 
mass spectrometric response of Dyn A (l-10) amide 
standard as a function of the amount applied to the 
sample probe tip revealed an approximate linear rela- 
tionship (Figure 3) in the 10 fmole to 1 pmole range, 
suggesting that such quantitative analysis may be fea- 
sible. 
Conclusions 
The mass spectra obtained from human plasma spiked 
with dynorphin peptides and from dynorphin process- 
ing studies in human blood demonstrate that matrix- 
assisted laser desorption mass spectrometry is a pow- 
erful analytical tool for studying the biotransformation 
of these ‘neuropeptides. The technique allows simulta- 
neous mass determination and identification of all sig- 
nificant peptide components in a mixture of biotrans- 
formation products. These measurements can be made 
rapidly from a variety of biologic materials with mini- 
mal requirement for purification of the sample. 
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